Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes

Diabetic Medicine

Volumn 19, Issue 10, 2002, Pages 847-852

  Manning, P J ^a   Sutherland, W H F ^a,b   Allum, A R ^a   De Jong, S A ^a   Jones, S D ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Department of Medical and Surgical Sciences   (New Zealand)

Author keywords

C reactive protein; Cell adhesion molecules; Diabetes; Hormone replacement therapy

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; LEUKOCYTE COUNT; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LEUKOCYTE COUNT; LINEAR MODELS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; STATISTICS, NONPARAMETRIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036400607     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00808.x     Document Type: Article

References (32)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. J Am Med Soc 1979; 241: 2035-2038.
2. Bierman EL. Atherogenesis in diabetes. Arterioscl Thromb 1992; 12: 647-656.
3. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
4. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-3078.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
7. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
8. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 531: 88-92.
9. Fasching P, Waldhausal W, Wagner OF. Elevated circulating adhesion molecules in NIDDM: potential mediators in diabetic macroangiopathy. Diabetologia 1996; 39: 1242-1244.
10. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 1997; 46: 2096-2101.
11. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes. The Hoorn Study. Diabetes 2000; 49: 485-491.
12. Patel SS, Thiagarajan R, Willerson JT, Yeh ETH. Inhibition of α4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 1998; 97: 75-81.
13. Lawrenson RA, Leydon GM, Newson RB, Feher MD. Coronary heart disease in women with diabetes. Diabetes Care 1999; 22: 856-857.
14. Kaplan RC, Heckbert SR, Weiss NS, Wahl PW, Smith NL, Newton KM et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 1998; 21: 1117-1121.
15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
16. Van Baal WM, Kenemans P, van der Mooren M, Kessel H, Emeis JJ, Stenhouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-928.
17. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-722.
18. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-218.
19. Manning P, Allum A, Jones S, Sutherland WHF, Williams S. Effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomised placebo controlled trial. Arch Intern Med 2001; 161: 1772-1776.
20. Guder WG, Narayanan S, Wisser H, Zawta B. List of analytes; pre-analytical variables. Brochure. In Samples: from the Patient to the Laboratory. Darmstadt: GIT Verlag, 1996.
21. Lipid Research Clinics' Program. Lipids and lipoprotein analysis. DHEW Publications N0. (NIH) 75-628, NIH 1. Bethesda, MD: National Heart and Lung Institute, 1974; 51-71.
22. 2+ precipitation procedure for quantification of high density lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388.
23. Fliess JL. The Design and Analysis of Clinical Experiments. New York: John Wiley, 1986.
24. Sattar N, Perera M, Small M, Lumsden M-A. Hormone replacement therapy and sensitive C-reactive protein in women with type-2 diabetes. Lancet 1999; 354: 487-488.
25. Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br J Obstet Gynaecol 1997; 104: 4-13.
26. Haverkate F, Thompson SG, Pyke SM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
27. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
28. Weinhold B, Rüther U. Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene. Biochem J 1997; 327: 425-429.
29. Van Baal WM, Emeis JJ, Kenemans P, Kessel H, Peters-Muller ERA, Schalkwijk CG et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999; 29: 913-921.
30. Guzic Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L. Hormone replacement therapy (HRT) reduces expression of cell adhesion molecules in healthy postmenopausal women. In Stemme S, Olsson AG eds. Atherosclerosis XII, Excerpta Medica, International Congress Series 1215. Amsterdam: Elsevier, 2000; 283 (Abstr.).
31. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
32. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink G-J et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999; 100: 96-102.